

Table 1. A brief overview of the case report.

The patient presented to a neurologist	Back pain and inability to walk
MRI	Partial collapse of 11th thoracic vertebra with cord compression
Referred to neurosurgeon	Laminectomy plus internal fixation
Histopathology	Metastatic follicular ca thyroid
Radiotherapy	20 Gy given to 10-12th thoracic vertebrae
Ultrasound and CT neck	No lesion detected in thyroid
Bone scan	Uptake in 11th thoracic vertebra
Patient underwent total thyroidectomy	No malignancy found on histopathology
Tg levels measured	>6,000 ng/ml
RAI administered	7.4 GBq
Whole body scan	Uptake in thyroid bed and the lower thoracic vertebral region
Tg levels measured	408 ng/ml
Repeat dose of I-131 after 1 year	7.4 GBq
Whole body scan	Uptake in the region of the lower thoracic vertebra only
Tg levels measured	236 ng/ml




Figure 1. MRI of the patient revealing collapse of 11th thoracic vertebra (arrow).




Figure 2. Immunohistochemistry staining showing Tg positivity (left panel) and TTF-1 staining (right panel) in the laminectomy sample.




Figure 3. *99mTc-MDP whole body bone scan showing intensely increased tracer uptake in the 11th thoracic vertebra.*

with metastasis in the region of the lower thoracic vertebral region (Figure 4). Post-RAI Tg levels came down to 408 ng/ml. Six months later repeat blood test revealed Tg levels of 203 ng/ml (Anti-Tg = 0.02 IU/ml). A repeat of Tg levels at 1 year revealed an increase to 250 ng/ml (Anti-Tg = 2.8 IU/ml). It was decided that another dose of 7.4 MBq of RAI be given to the patient. The whole-body scan revealed uptake in the surgical site, with no other focus of abnormal tracer uptake noted (Figure 5). The post-second dose Tg decreased slightly to 236 ng/ml (Anti-Tg = 3.07 IU/ml) (Table 1).

Discussion

Nearly a third of patients with cancer have a distant spread of the disease [12]. As many as 3%-4% of patients with bone metastasis have no identifiable primary tumor [13]. We report a case of metastasis of follicular cancer of the thyroid to the spine. However, when the thyroid gland was removed and histopathology performed, no primary tumor was discovered. In the review of the literature, one




Figure 4. *Post-ablation scan after administration of the first dose of 7.4 GBq of I-131 showing uptake in the thyroid bed (arrowhead) and the region of the lower thoracic vertebrae (outline arrow).*

case series of seven cases of metastatic papillary thyroid cancer was found where no primary tumor could be found [14]. Boz et al. [15] have also reported a case of metastatic follicular cancer of the thyroid without an identifiable primary. Akdemir et al. [10] have reported a case where there were skeletal metastases in a patient without any primary being detected in the thyroid. In a 2012 study published in the Australia and New Zealand Journal of Surgery, regarding papillary thyroid cancer patients, three patients were reported to have distant metastasis without any discernible




Figure 5. Post-ablation scan after the second dose of 7.4 GBq of I-131 still revealing uptake in the operation site.

primary lesion [8]. Meanwhile, Anastasilakis et al. have reported a patient in whom they found lymph node metastasis of papillary cancer without any discernible primary [16].

It is rare to have a metastatic spread of the disease in follicular thyroid cancer without a primary. The lack of the detectable primary may be because of the spontaneous regression of the primary lesion.

Conclusion

This case report highlights that in cases of metastasis from an unknown primary, follicular thyroid cancer should be included in the differential diagnosis. Also, even if a

primary is not found in the thyroid, total thyroidectomy with post-surgical administration of RAI can lead to a good prognosis as measured by the serum Tg levels.

What is new?

Follicular thyroid cancer must be a differential in the case of metastasis of unknown origin. There may be instances where a primary may not be found in the thyroid upon total thyroidectomy. Administration of RAI in such cases can lead to a good prognosis.

List of Abbreviations

Anti-Tg	Anti-thyroglobulin antibodies
CT	Computed tomography
GBq	Gigabecquerels
MBq	Megabecquerels
MRI	Magnetic resonance imaging
RAI	Radioactive iodine
Tg	Thyroglobulin

Conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Funding

This research did not receive any funding or grant.

Consent for publication

A written informed consent to publish/present this case was obtained from the patient.

Ethical approval

Ethical approval is not required at our institutions to publish an anonymous case report.

Author details

Javaid Iqbal¹, Basit Iqbal², Talal A. Rahman¹, Salman Habib¹, Hasnain Dilawar¹, Imran Hadi¹, Akhtar Ahmad¹

1. Department of Nuclear Medicine, KIRAN, Karachi, Pakistan
2. Department of Nuclear Medicine, GINUM, Gujranwala, Pakistan

References

1. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. *J Cancer Epidemiol*. 2013;2013:965212. <https://doi.org/10.1155/2013/965212>
2. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. *Cancer Causes Control*. 2009;20(5):525-31. <https://doi.org/10.1007/s10552-008-9260-4>
3. Rubab N, Afzal M, Shahbaz M, Imran M. Complete remission after primary single dose of radioactive iodine in metastatic papillary thyroid carcinoma: a case report. *Eur J Med Case Rep*. 2021;345-9. <https://doi.org/10.24911/ejmcr/173-1630476749>
4. Choksi P, Papaleontiou M, Guo C, Worden F, Banerjee M, Haymart M. Skeletal complications and mortality in thyroid cancer: A population-based study. *J Clin Endocrinol Metab*. 2017;102(4):1254-1260. <https://doi.org/10.1210/jc.2016-3906>

5. Benbassat CA, Mechlis-Frish S, Hirsch D. Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. *World J Surg*. 2006;30(6):1088–95. <https://doi.org/10.1007/s00268-005-0472-4>
6. Chen D, Huang L, Chen S, Huang Y, Hu D, Zeng W, et al. Innovative analysis of distant metastasis in differentiated thyroid cancer. *Oncol Lett*. 2020;19(3):1985–92. <https://doi.org/10.3892/ol.2020.11304>
7. Ramadan S, Ugas MA, Berwick RJ, Notay RJ, Cho H, Jerjes W, et al. Spinal metastasis in thyroid cancer. *Head Neck Oncol*. 2012;4(1):1–19. <https://doi.org/10.1186/1758-3284-4-39>
8. Ban EJ, Andrabi A, Grodski S, Yeung M, McLean C, Serpell J. Follicular thyroid cancer: minimally invasive tumours can give rise to metastases. *ANZ J Surg*. 2012;82(3):136–9. <https://doi.org/10.1111/j.1445-2197.2011.05979.x>
9. O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. *World J Radiol*. 2015;7(8):202–11. <https://doi.org/10.4329/wjr.v7.i8.202>
10. Akdemir I, Erol FS, Akpolat N, Ozveren MF, Akfirat M, Yahsi S. Skull metastasis from thyroid follicular carcinoma with difficult diagnosis of the primary lesion. *Neurol Med Chir (Tokyo)*. 2005;45(4):205–8. <https://doi.org/10.2176/nmc.45.205>
11. Kallel F, Hamza F, Charfeddine S, Amouri W, Jardak I, Ghorbel A, et al. Clinical features of bone metastasis for differentiated thyroid carcinoma: a study of 21 patients from a Tunisian center. *Indian J Endocrinol Metab*. 2014;18(2):185–90. <https://doi.org/10.4103/2230-8210.129109>
12. Tomuleasa C, Zaharie F, Muresan M-S, Pop L, Fekete Z, Dima D, et al. How to diagnose and treat a cancer of unknown primary site. *J Gastrointest Liver Dis*. 2017;26(1):69–79. <https://doi.org/10.15403/jgld.2014.1121.261.haz>
13. Hage WD, Abouafia AJ, Abouafia DM. Incidence, location, and diagnostic evaluation of metastatic bone disease. *Orthope Clin North Am*. 2000;31(4):515–28. [https://doi.org/10.1016/S0030-5898\(05\)70171-1](https://doi.org/10.1016/S0030-5898(05)70171-1)
14. Xu B, Scognamiglio T, Cohen PR, Prasad ML, Hasanovic A, Tuttle RM, et al. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon. *Hum Pathol*. 2017;65:133–9. <https://doi.org/10.1016/j.humpath.2017.05.013>
15. Boz A, Tazegul G, Bozoglan H, Dogan O, Sari R, Altunbas HA, et al. Bone metastases without primary tumor: A well-differentiated follicular thyroid carcinoma case. *J Cancer Res Thera*. 2018;14(2):447–50. <https://doi.org/10.4103/0973-1482.199391>
16. Anastasilakis AD, Polyzos SA, Makras P, Kamps L, Valeri RM, Dimitrios K, et al. Papillary thyroid microcarcinoma presenting as lymph node metastasis—a diagnostic challenge: case report and systematic review of literature. *Hormone (Athens)*. 2012;11(4):419–27. <https://doi.org/10.14310/horm.2002.1373>

Summary of the case

1	Patient (gender, age)	Male, 60 years
2	Final diagnosis	Metastatic papillary ca thyroid
3	Symptoms	Backache and inability to walk
4	Medications	RAI
5	Clinical procedure	Surgery
6	Specialty	Nuclear Medicine